Literature DB >> 21316162

Synthetic cannabinoid JWH-018 and psychosis: an explorative study.

Susanna Every-Palmer1.   

Abstract

BACKGROUND: Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded "herbal incense", they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms.
METHOD: This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service.
RESULTS: All 15 subjects were familiar with a locally available JWH-018 containing product called "Aroma" and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was "natural" and "safe". Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms.
CONCLUSION: It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316162     DOI: 10.1016/j.drugalcdep.2011.01.012

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  50 in total

1.  Convulsions associated with the use of a synthetic cannabinoid product.

Authors:  Aaron B Schneir; Todd Baumbacher
Journal:  J Med Toxicol       Date:  2012-03

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

3.  Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Authors:  Jason M Wiebelhaus; Justin L Poklis; Alphonse Poklis; Robert E Vann; Aron H Lichtman; Laura E Wise
Journal:  Drug Alcohol Depend       Date:  2012-07-07       Impact factor: 4.492

4.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 5.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 6.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

7.  K2 toxicity: fatal case of psychiatric complications following AM2201 exposure.

Authors:  Amy L Patton; Krishna C Chimalakonda; Cindy L Moran; Keith R McCain; Anna Radominska-Pandya; Laura P James; Charles Kokes; Jeffery H Moran
Journal:  J Forensic Sci       Date:  2013-07-03       Impact factor: 1.832

8.  Risk management strategies of synthetic cannabis users.

Authors:  Stephanie Campos; Ellen Benoit; Eloise Dunlap
Journal:  Drugs Alcohol Today       Date:  2019-09-02

9.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

10.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.